Biotech RadarJobs updated

COMPANY

Verrica Pharmaceuticals

HQ: West Chester, PA source · verrica.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: oncology dermatology skin cancer molluscum contagiosum Common Warts Common Warts (Verruca Vulgaris) Human Papilloma Virus Warts Papillomavirus Infections Viral Skin Diseases Infectious Skin Diseases Skin Diseases Basal Cell Carcinoma Basal Cell Cancer of the Skin Cancer of the Skin Warts Hand DNA Virus Infections Virus Diseases Verruca Vulgaris Verruca Condylomata Acuminata Viral Sexually Transmitted Diseases Sexually Transmitted Diseases Cantharidin VP-102

Location: West Chester, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$92.0MRaised (2 yrs)9Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) source ↗
  2. Trial start Phase 3: Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) source ↗
  3. Trial start Phase 3: Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) source ↗
  4. Raise Private placement: $50M (total, as published), announced Nov 24, 2025. Source: SEC filing. source ↗ · Form D filed Dec 10, 2025 SEC Form D ↗
  5. Partnership Partnership / licensing: upfront not published; stated deal value $8M (kept separate from upfront), announced Jul 1, 2025. Source: SEC filing. source ↗
  6. Raise Follow-on offering: $42M (total, as published), announced Nov 21, 2024. Source: SEC filing. source ↗
  7. Trial start Phase 2: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma source ↗
  8. Trial start Phase 2: A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts source ↗
  9. Trial start Phase 2: Cantharidin and Occlusion in Verruca Epithelium source ↗
  10. Trial start Phase 3: Cantharidin Application in Molluscum Patients-1 source ↗
  11. Trial start Phase 3: Cantharidin Application in Molluscum Patients source ↗
  12. Trial start Phase 2: Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $92.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT07637734Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)Phase 3RecruitingJun 15, 20262027-05 (estimated)
NCT07457918Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)Phase 3RecruitingMar 11, 2026Apr 30, 2028 (estimated)
NCT07246590Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Phase 3RecruitingDec 17, 20252027-06 (estimated)
NCT05188729Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaPhase 2CompletedFeb 1, 2022Apr 15, 2024 (actual)
NCT03487549Cantharidin and Occlusion in Verruca EpitheliumPhase 2CompletedMar 27, 2018May 16, 2019 (actual)
NCT03981822A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital WartsPhase 2CompletedJun 25, 2019May 21, 2020 (actual)
NCT03377790Cantharidin Application in Molluscum Patients-1Phase 3CompletedMar 21, 2018Nov 26, 2018 (actual)
NCT03377803Cantharidin Application in Molluscum PatientsPhase 3CompletedFeb 14, 2018Sep 26, 2018 (actual)
NCT03186378Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.Phase 2CompletedJun 8, 2017Jun 25, 2018 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback